Highlights

•

Epithelial-mesenchymal transition (EMT) is a mechanism of chemoresistance.

•

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) use can trigger EMT and EMT can consequently confers resistance.

•

EGFR-TKI use alters protein or miRNA expression or activity, promoting EMT.

•

EMT is associated with altered effector protein expression, leading to resistance.

Washington, D.C. | 22 January 2026 – Sujuan Ba, CEO of the National Foundation for Cancer Research (NFCR), has been named to OncoDaily’s list of the 100 Most Influential CEOs in Oncology in 2025, recognizing leaders whose work is shaping the global cancer research and care ecosystem.

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole chromosomes, changes that help tumors grow, adapt and resist treatment. In a study published in Nature Communications, scientists describe a computational approach called ALFA-K that uses longitudinal, single-cell data to reconstruct how cancer cells move through different chromosome states over time and identify which configurations are favored by evolution.

Cancer vaccine may offer new prevention strategy for patients with Lynch syndrome

Novel immunotherapy overcomes treatment resistance in multiple types of cancer

Engineered nanobodies improve respiratory defenses against multiple viruses

New combination treatments show promise for patients with early-stage Hodgkin lymphoma and breast cancer

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells directly, it targets the cells that protect them. The study, published in the January 22 online issue of Cancer Cell, a Cell Press Journal [DOI 10.1016/j.ccell.2025.12.021], was conducted in aggressive preclinical models of metastatic ovarian and lung cancer. It points to a new strategy for treating advanced-stage solid tumors. In a strategy modeled after the famed Trojan horse, the treatment enters the tumors by targeting cells called macrophages that guard the cancer cells, disarms these protectors, and opens up the tumor’s gates for the immune system to enter and wipe out the cancer cells.